Collegium Pharmaceutical Inc
NASDAQ:COLL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
ZheJiang Haers Vacuum Containers Co Ltd
SZSE:002615
|
CN |
|
Svenska Cellulosa SCA AB
STO:SCA B
|
SE |
|
Aditya Birla Capital Ltd
NSE:ABCAPITAL
|
IN |
Collegium Pharmaceutical Inc
Accounts Payable
Collegium Pharmaceutical Inc
Accounts Payable Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accounts Payable | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Collegium Pharmaceutical Inc
NASDAQ:COLL
|
Accounts Payable
$10.7m
|
CAGR 3-Years
45%
|
CAGR 5-Years
1%
|
CAGR 10-Years
12%
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Accounts Payable
$12B
|
CAGR 3-Years
7%
|
CAGR 5-Years
7%
|
CAGR 10-Years
7%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Accounts Payable
$3.6B
|
CAGR 3-Years
6%
|
CAGR 5-Years
6%
|
CAGR 10-Years
9%
|
|
|
Pfizer Inc
NYSE:PFE
|
Accounts Payable
$5.2B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
4%
|
CAGR 10-Years
4%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Accounts Payable
$4.4B
|
CAGR 3-Years
1%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
6%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Accounts Payable
$5.4B
|
CAGR 3-Years
41%
|
CAGR 5-Years
27%
|
CAGR 10-Years
15%
|
|
Collegium Pharmaceutical Inc
Glance View
Collegium Pharmaceutical, Inc. operates as a pharmaceutical company. The company is headquartered in Stoughton, Massachusetts and currently employs 152 full-time employees. The company went IPO on 2015-05-07. Collegium is a diversified, specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions. The firm's product portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta ER and Nucynta IR (Nucynta Products), which are extended-release (ER) and immediate-release (IR) formulations of tapentadol. Xtampza ER is formulated using its abuse-deterrent technology platform, DETERx. Xtampza ER is for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. Nucynta ER is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment, including neuropathic pain. Nucynta IR is indicated for the management of acute pain severe enough to require an opioid analgesic.
See Also
What is Collegium Pharmaceutical Inc's Accounts Payable?
Accounts Payable
10.7m
USD
Based on the financial report for Dec 31, 2025, Collegium Pharmaceutical Inc's Accounts Payable amounts to 10.7m USD.
What is Collegium Pharmaceutical Inc's Accounts Payable growth rate?
Accounts Payable CAGR 10Y
12%
Over the last year, the Accounts Payable growth was 171%. The average annual Accounts Payable growth rates for Collegium Pharmaceutical Inc have been 45% over the past three years , 1% over the past five years , and 12% over the past ten years .
